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INFLUENCE OF INSULIN RESISTANCE ON
HYPERTENSION IN DIABETICS
Laure d’Este`ve-Bonetti, Jacques Amar, He´le`ne Hanaire-Broutin,
Thierry Brillac, Catherine Calazel-Fournier, Gise`le Hernandez, Michel
Salvador, Bernard Chamontin. 1Internal Medicine, Hoˆpital Purpan,
Toulouse, Hte Garonne, France, 2Diabetology, Hoˆpital Rangueil,
Toulouse, Hte Garonne, France
Multiple lines of evidence link high blood pressure and insulin resistance.
However the influence of insulin resistance on hypertension in type 2
diabetics remains to be assessed to compare insulin resistance in hyper-
tensive and normotensive patients with type 2 diabetes
The study group concerned 41 patients recruited in an outpatient clinic.
23 patients with BP.130/85 mmHg were identified as mild hypertensive
(20 from 23 under treatment). Insulin sensitivity was assessed with the
use of the euglycemic insulin-clamp technique and biologic parameters
such as lipids, PAI-1, insulin and proinsulin. An ambulatory blood
pressure monitoring was performed in all patients.
No significant difference was observed in age, body mass index, waist
circumference, and insulin sensitivity.
hypertensives normotensives p
Age 53,91 6 1,43 52,33 6 1,55 NS
BMI (kg/m2) 30.57 6 1,03 28,69 6 1,07 NS
waist circumference 106.22 6 2,57 101,82 6 2,53 NS
24h SBP (mmHg) 129,1 6 2,96 121,86 6 2,8 0.099
24h DBP (mmHg) 80,56 6 1,55 76,64 6 1,61 0.098
Triglycerides (g/l) 1,62 6 0,14 1,63 6 0,21 NS
PAI-1 (UI/ml) 26,27 6 1,97 28,5 6 2,4 NS
insulin (mUI/l) 25,62 6 18.83 22,63 6 14,66 NS
proinsulin (pmol/l) 29,62 6 26,61 32,69 6 18,5 NS
Clamp Rc (mg/kg/mn) 5,43 6 0,78 6,32 6 0,5 NS
In this selected population of type 2 diabetics, insulin resistance was
not significantly different between hypertensives and normotensives ; it is
suggested that normotensive and mild hypertensive type 2 diabetics may
present a similar degree of insulin resistance.
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OBESITY REGULATES RENAL ENDOTHELIN AND
ENDOTHELIN ETA RECEPTOR EXPRESSION IN
VIVO. DIFFERENTIAL EFFECTS OF CHRONIC ETA
RECEPTOR BLOCKADE
Jian Zhang, Livius V. d’Uscio, Sidney Shaw, Klaus Mu¨nter, Michael
Klainguti, Matthias Barton. 1Department of Medicine, University
Hospital Zurich, Zurich, Switzerland, 2Anaesthesia Research, Mayo
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ETA receptors have been implicated in obesity-associated hypertension
(Hypertension 1999; 33: 1169). We characterized the renal endothelin
system in diet-induced obesity and determined the effects of chronic
treatment with the ETA antagonist darusentan. C57BL/6J mice were fed
a standard diet (control) or a high-fat diet (Harlan TD88137) with or
without darusentan (50 mg/kg/d, 30 wk). Total RNA was extracted from
whole kidneys and mRNA expression of preproendothelin-1 (ppET-1),
ETA receptors, and b-actin were determined by RT-PCR using mouse-
specific primers. PCR-products were normalized vs. b-actin or 18S rRNA.
Renal ET-1 protein was measured by RIA/HPLC. High fat diet increased
body weight by 257% compared to 54% (control diet). Darusentan had no
effect on body weight in obese mice (263%) and treatments had no effect on
systolic blood pressure. Obesity was associated with upregulation of renal
ETA receptors (14465% vs 10067%, p,0.05 vs. control) and to a lesser
extent, preproendothelin-1 (11365% vs.10062%, p,0.05 vs. control). In
obese mice chronic darusentan treatment in part prevented the ETA receptor
upregulation (126% vs. 14465%, p,0.05) but had no significant effect on
ppET-1 mRNA expression (10169 vs. 10062%, n.s.). Renal ET-1 protein
increased in obese animals (from 190618 to 267619 pg/g tissue, p,0.05
vs. control). This increase was not affected by concomitant darusentan
treatment (n.s.).
These data for the first time demonstrate that obesity in normotensive
rats is associated with upregulation of renal ETA receptor expression
suggesting that body weight per se affects ET receptor expression in the
kidney. Our data further indicate that in this model ETA receptors control
expression of the ETA receptor but not the ppET-1 gene, suggesting
autocrine regulation in vivo. These mechanisms might contribute to the
pathogenesis of obesity-associated diseases affecting the kidney and/or
blood pressure.
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EFFECT OF ORLISTAT IN PATIENTS WITH
HYPERTENSION AND EITHER HIGH OR NORMAL
FASTING INSULIN LEVELS
Gerald M. Reaven, Karen R. Segal, Jonathan Hauptman, Mark N.
Boldrin, Charles P. Lucas. 1Medical Department, Roche Laboratories,
Nutley, NJ, United States
All 214 subjects with elevated blood pressure (BP)($140/$90 mmHg)
were selected from the total pool of overweight or obese individuals who
completed one year of treatment consisting of diet 1 placebo (P) or diet
1 orlistat (O). Compared to subjects with normal fasting insulin levels
(,90 pm/L), hypertensive subjects with high fasting insulin levels ($90
pm/L) had significantly higher (p,0.05) initial values for body weight,
fasting glucose, LDL-cholesterol (LDL-C), LDL/HDL-C, triglycerides
and systolic BP plus lower levels of HDL-C.
After 1 year, no significant differences were observed between O and P in
normal insulin subjects for changes in blood pressure, glucose, insulin or
lipids despite greater weight loss with O vs P (-10.361.0% vs -6.4 6 0.9%,
p50.0028). In high insulin subjects, the following changes were signifi-
cantly greater for O than P: body weight (-9.3 6 0.7% vs -5.2 6 0.6%,
p50.0001), systolic BP (-17.6 6 1.7 vs -12.6 6 1.8 mmHg, p50.035),
diastolic BP (-10.6 6 1.1 vs -8.5 6 1.2 mmHg, p50.022), insulin (-39 6 5.8
vs -25 6 7.5 pm/L, p50.013), LDL-C (-0.49 6 0.09 vs -0.18 6 0.08 mm/L,
p50.035), or LDL/HDL-C (-0.44 6 0.09 vs -0.09 6 0.09, p50.044).
In conclusion, CV risk factors are more likely to be abnormal in high
insulin hypertension, and orlistat was more effective than placebo in
improving these risk factors.
Consultant: Roche Labs
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CARDIOVASCULAR EVENTS AND ABNORMALITIES
OF GLUCOSE METABOLISM IN PATIENTS WITH
HYPERTENSIVE NEPHROSCLEROSIS AND REDUCED
CREATININE CLEARANCE
Laura Zingaro, Cristiana Catena, Daniele Casaccio, Sergio De
Marchi, Leonardo A. Sechi. 1Internal Medicine, DPMSC, University of
Udine, Udine, Italy
Abnormalities of glucose metabolism and hyperinsulinemia have been
demonstrated in patients with end-stage renal disease and may contribute
to the development of atherosclerotic complications in these patients.
This study was performed in hypertensive patients with mild to moderate
impairment of renal function to investigate at what stage of renal failure
abnormalities of glucose metabolism develop and whether these abnormal-
ities are associated with increased prevalence of cardiovascular events. In
321 untreated essential hypertensive patients recruited at a hypertension
clinic and 92 matched normotensive controls we assessed the renal function
by measurement of 24-hour creatinine clearance, urinary protein excretion,
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